Slingshot members are tracking this event:
OPK's Phase 1/2a Study to Assess FVIIa (MOD-5014) in Adult Men With Hemophilia A or B set for March 2017 primary completion date
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
• Phase 2a trial for intravenously administered Factor VII-CTP and Phase 1 trial for subcutaneously administered Factor VII-CTP ongoing.
Slingshot Insights Explained
Sep 28, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Hemophilia A, Hemophilia B, Phase 1/2 Study